OncoSec Secures License for Electroporation Intellectual Property from University of South Florida

    OncoSec Secures License for Electroporation Intellectual Property from
                         University of South Florida

Exclusive License Extends Patent Protection for ImmunoPulse Technology

PR Newswire

SAN DIEGO, Sept. 11, 2012

SAN DIEGO, Sept. 11, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS),
a company developing its advanced-stage ImmunoPulse and NeoPulse therapies to
treat solid tumor cancers, announced it has secured an exclusive license for
specific patented technology from the University of South Florida Research
Foundation (USFRF) relating to the delivery of gene-based therapeutics via
intratumoral and intramuscular electroporation. This patent is directly
related to the ongoing Phase II trials for metastatic melanoma, Merkel cell
carcinoma and cutaneous T-cell lymphoma using the company's ImmunoPulse
therapy, and extends patent protection for the ImmunoPulse technology to the
year 2024. Financial terms of this agreement were not disclosed.

(Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO)

OncoSec's proprietary gene and drug delivery platform, the OncoSec Medical
System (OMS) electroporation device, is currently being used to develop the
company's ImmunoPulse and NeoPulse therapies. This platform encompasses
patents, technology and other intellectual property for intratumoral methods
for delivering drugs and gene-based treatments in humans.

ImmunoPulse involves the application of a brief electric field to the surface
of the skin. This temporarily opens pores in the cell membrane, allowing
anti-cancer agent DNA IL-12, to be absorbed more efficiently. DNA IL-12, which
normally has difficulty penetrating the tumor cell membrane to get inside
these cells, has been shown to significantly stimulate the immune system's
T-cells to fight the cancer. The new license from USFRF complements OncoSec's
seminal patents, particularly for the protection of the methods involved in
the ImmunoPulse treatment, and specifically for the use of DNA IL-12.

"Our licensing agreement with the USFRF significantly strengthens OncoSec's
intellectual property rights in the area of gene and drug delivery via in vivo
electroporation," said Punit Dhillon, OncoSec's President and CEO. "We
anticipate that the further development of this technology will enhance the
ability of ImmunoPulse to address the serious unmet need among patients with
skin cancer. OncoSec's patent portfolio places us in a preeminent position
within the field of electroporation-based delivery of gene-based treatments
for cancer."

"OncoSec is the ideal choice to further develop this technology that I and my
colleagues pioneered while working at the University of South Florida, and I
am pleased they have secured this license," said Richard Heller, Ph.D., author
of the patented technology. "The technology involves short-pulsed electric
fields that can deliver plasmid DNA to stimulate the immune system. As a
result, it is a natural fit with OncoSec's ongoing program to develop its
ImmunoPulse therapy." 

About OncoSec Medical Inc.

OncoSec Medical Incorporated isa biopharmaceutical companydeveloping its
advanced-stage ImmunoPulse, NeoPulse therapies to treat solid tumor cancers
and metastatic disease.ImmunoPulse and NeoPulse therapiesaddress an unmet
medical needandrepresenta potential solution, for less invasive and less
expensive therapies that are able to minimize detrimental effects resulting
from currently available cancer treatments such as surgery, systemic
chemotherapy or immunotherapy and other treatment alternatives. OncoSec's
core technology is based upon its proprietaryuse of anelectroporation
platform todramatically enhancethedelivery and uptake of a locally
delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic
agent(NeoPulse). Treatment ofvarious solid cancersusing these powerfuland
targetedanti-cancer agentshas demonstratedselective destruction of
cancerous cellswhile sparing healthy normal tissues during early and late
stage clinical trials. OncoSec's clinical programs include three Phase II
clinical trials for ImmunoPulse targeting lethal skin cancers. More
information is available at http://www.oncosec.com/Additional information may
also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.

This press release contains forward looking statements within the meaning of
the U.S. Private Securities Litigation Reform Act of 1995. Any statements in
this release that are not historical facts may be considered such "forward
looking statements." Forward looking statements are based on management's
current preliminary expectations and are subject to risks and uncertainties
which may cause our results to differ materially and adversely from the
statements contained herein. Some of the potential risks and uncertainties
that could cause actual results to differ from those predicted include our
ability to raise additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical studies and
clinical trials, unexpected new data, safety and technical issues, competition
and market conditions. These and additional risks and uncertainties are more
fully described in OncoSec's filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward looking statements
which speak only as of the date they are made. OncoSec disclaims any
obligation to update any forward looking statements to reflect new
information, events or circumstances after the date they are made, or to
reflect the occurrence of unanticipated events.

SOURCE OncoSec Medical Inc.

Website: http://www.oncosec.com
Contact: For OncoSec: Amy Chan, Director, Corporate Communications,
855-OncoSec +1-855-662-6732, investors@oncosec.com, For Media and Public
Relations: Laura Radocaj, lradocaj@dgicomm.com, DGI: +1-212-825-3210
Press spacebar to pause and continue. Press esc to stop.